Literature DB >> 8280823

Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome.

J Hammer1, S F Phillips, N J Talley, M Camilleri.   

Abstract

In some patients with the irritable bowel syndrome, rectal urgency and discomfort are major clinical problems and, under experimental conditions, these symptoms are perceived at lesser volumes of rectal distension than they are in asymptomatic controls. Further, a 5-hydroxytryptamine type-3 receptor antagonist increased the threshold for rectal discomfort in irritable bowel syndrome. Our aims were, (a) to measure rectal sensation during isobaric distensions of the rectum, and (b) to test the effect of another selective 5HT3-antagonist, ondansetron 0.15 mg/kg, on rectal sensitivity, colonic tone, rectal tone and manometric responses. Ten healthy volunteers and five patients with diarrhoea-predominant irritable bowel syndrome were studied. A multilumen barostat-manometric assembly was placed in the descending colon, and a second barostat balloon was positioned in the rectum. Tone in the wall of the colon and rectum was measured by the barostat balloon volume during a constant pressure clamp, while intraluminal pressures were recorded by manometry; perceived sensations were also recorded before and after the intravenous administration of ondansetron or placebo in blinded fashion. Rectal resistance to stretch was greater and rectal urgency was induced by lower distending pressures in irritable bowel syndrome, however, basal tone in the rectum was similar in health and irritable bowel syndrome. Ondansetron did not change rectal sensitivity (first sensation or urgency) or tone. Rectal distension did not alter tone in the descending colon or colonic manometry; ondansetron did not influence any index of colonic function.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8280823     DOI: 10.1111/j.1365-2036.1993.tb00131.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  17 in total

1.  Lack of an Effect of Gastric Capsaicin on the Rectal Component of the Gastrocolonic Response.

Authors:  Martina Führer; Johann Hammer
Journal:  Dig Dis Sci       Date:  2017-10-30       Impact factor: 3.199

Review 2.  The non-antiemetic uses of serotonin 5-HT3 receptor antagonists. Clinical pharmacology and therapeutic applications.

Authors:  A J Greenshaw; P H Silverstone
Journal:  Drugs       Date:  1997-01       Impact factor: 9.546

Review 3.  The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.

Authors:  James H Lewis
Journal:  Drug Saf       Date:  2011-07-01       Impact factor: 5.606

4.  Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial.

Authors:  G Stacher; U Weber; G Stacher-Janotta; P Bauer; K Huber; A Holzäpfel; G Krause; C Steinborn
Journal:  Br J Clin Pharmacol       Date:  2000-05       Impact factor: 4.335

Review 5.  The role of experimental models in developing new treatments for irritable bowel syndrome.

Authors:  Daniel P Holschneider; Sylvie Bradesi; Emeran A Mayer
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 3.869

6.  Visceral sensitivity in irritable bowel syndrome and healthy volunteers: reproducibility of the rectal barostat.

Authors:  Signe Spetalen; Morten B Jacobsen; Morten H Vatn; Svein Blomhoff; Leiv Sandvik
Journal:  Dig Dis Sci       Date:  2004-08       Impact factor: 3.199

7.  Brain functional magnetic resonance imaging of rectal pain and activation of endogenous inhibitory mechanisms in irritable bowel syndrome patient subgroups and healthy controls.

Authors:  C H Wilder-Smith; D Schindler; K Lovblad; S M Redmond; A Nirkko
Journal:  Gut       Date:  2004-11       Impact factor: 23.059

Review 8.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

9.  Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism.

Authors:  J Zighelboim; N J Talley; S F Phillips; W S Harmsen; A R Zinsmeister
Journal:  Dig Dis Sci       Date:  1995-04       Impact factor: 3.199

10.  Investigation of the 5-hydroxytryptamine receptor mediating the "transient" short-circuit current response in guinea-pig ileal mucosa.

Authors:  E Leung; D Blissard; M F Jett; R M Eglen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-06       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.